Investigating a new treatment target for aggressive prostate cancer
A novel mitotic regulatory axis in neuroendocrine prostate cancer
This study is looking at a tough type of prostate cancer called neuroendocrine prostate cancer (NEPC) to see how a protein named PKD affects its growth and resistance to treatments, with the goal of finding new ways to help patients like you through potential new therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10636919 on NIH RePORTER |
What this research studies
This research focuses on neuroendocrine prostate cancer (NEPC), a severe form of prostate cancer that often arises from earlier stages of the disease and is resistant to standard treatments. The study aims to explore the role of a specific protein, PKD, in the development and progression of NEPC. By understanding how PKD influences tumor growth and resistance to therapies, researchers hope to identify new treatment strategies using PKD inhibitors. Patients may be involved in trials that assess the effectiveness of these novel therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with neuroendocrine prostate cancer or those with metastatic castration-resistant prostate cancer who have developed treatment-related NEPC.
Not a fit: Patients with early-stage prostate cancer or those whose cancer has not progressed to the neuroendocrine subtype may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with neuroendocrine prostate cancer, improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other cancers, suggesting that this approach may yield beneficial results for NEPC as well.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Wang, Qiming Jane — University of Pittsburgh at Pittsburgh
- Study coordinator: Wang, Qiming Jane
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.